1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Fanconi Anemia, Complementation Group N: new trials by email Literature Review of Fanconi Anemia, Complementation Group N trials Research Report on Fanconi Anemia, Complementation Group N
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer Carboplatin, Olaparib - Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | Phase 2 | Recruiting | VA Office of Research and Development | 100 | 2019-10-01 | 2026-09-17 |
Fanconi Anemia, Complementation Group D1 (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Prostatic Neoplasms (1)
Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Heredodegenerative Disorders, Nervous System (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Malformations (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Peripheral Nervous System Diseases (1)
Carboplatin (1) · olaparib (1)
VA Office of Research and Development (1)
United States (1)
Maneesh Jain, MD (1) · Phoebe Tsao, MD MSc (1) · Robert B. Montgomery, MD (1) · Ryan Burri, MD (1)